Related Experiment Video
Updated: Jun 17, 2025
Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice
Published on: April 21, 2015
Lifestyle Intervention Modulates the CD4+ T Cell Profile in the Blood of Crohn's Disease Patients
Alexandra Mekes-Adamczyk1, Nadine Gausmann1, Özlem Öznur2,3
1Institute of Medical Microbiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Insights
A mind-body medicine (MBM) program improved the CD4+ T cell profile in Crohn's disease (CD) patients, comparable to healthy individuals. This lifestyle intervention showed potential benefits for immune status and quality of life in CD management.
Area of Science:
- Immunology
- Gastroenterology
- Integrative Medicine
Background:
- Crohn's disease (CD) impacts patient well-being, with stress and lifestyle factors influencing disease activity.
- An imbalance in CD4+ T cell responses is central to CD pathogenesis.
- Stress is known to modulate CD4+ T cell function, underscoring the need for interventions.
Purpose of the Study:
- To assess the impact of a mind-body medicine (MBM) stress management and lifestyle modification program on the CD4+ T cell profile in CD patients.
- To investigate the relationship between quality of life improvements and immunological changes.
- To compare the effects of guided versus self-directed MBM interventions.
Main Methods:
- Analysis of circulating CD4+ T cells using flow cytometry post-MBM program.
- Randomized controlled trial over 9 months with a guided intervention group (IG) and a self-guided waitlist control group (CG).
- Comparison of CD patient T cell profiles with those of healthy blood donors.
Main Results:
- The MBM program led to a reduction in regulatory T cell (Treg) frequencies in CD patients.
- A significant correlation was observed between improved quality of life and Treg frequencies in the guided IG.
- Differential expression of gut-homing molecules (GPR15, CCR9) was noted on Tregs and CD4+ effector T cells in both groups.
Conclusions:
- The MBM program, in both guided and self-directed formats, may help normalize the CD4+ T cell profile in CD patients towards that of healthy individuals.
- Lifestyle interventions show promise for improving CD progression, symptoms, and immunological status.
- Further research is warranted to confirm these findings and elucidate their clinical significance.
Background:
Crohn's disease (CD) significantly affects patients' well-being and is influenced by stress and lifestyle factors, highlighting the importance of improving quality of life in CD management. An imbalance between pro- and anti-inflammatory CD4+ T cell responses is a key factor in CD, and stress has been shown to alter the function of CD4+ T cells. Therefore, this study aimed to evaluate the effect of a mind-body medicine stress management and lifestyle modification (MBM) program on the CD4+ T cell profile in CD patients.
Methods:
Circulating CD4+ T cells from CD patients were analyzed by flow cytometry following the MBM program. Patients were randomly assigned to either a guided intervention group (IG) or a self-guided waitlist control group (CG) over a 9-month trial and compared with healthy blood donors.
Results:
Lifestyle intervention reduced regulatory T cell (Treg) frequencies in the blood of CD patients. Notably, we observed a significant correlation between the quality of life improvement and Treg frequencies in the IG but not in the CG. Furthermore, differential activation and expression of the gut-homing molecules G protein-coupled receptor 15 and CCR9 on circulating Tregs and CD4+ effector T cells were detected in both the IG and CG.
Conclusions:
The MBM program, whether guided or self-directed, has the potential to restore the CD4+ T cell profile of CD patients to levels comparable to healthy blood donors. Lifestyle interventions may benefit CD progression, symptoms, and immunological status, but further analysis is needed to substantiate these findings and to fully understand their clinical implications. (ClinicalTrials.gov: NCT05182645).
More Related Videos
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...